Peptides News and Research

RSS

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Biolauncher, Isogenica and Cresset enter joint venture to develop drug discovery platform

Isogenica Ltd today announced a collaborative joint venture with Biolauncher Ltd and Cresset Biomolecular Discovery Ltd to develop an innovative end-to-end therapeutic discovery platform.

28 Jun 2011

TrialNet presents Diamyd Phase II study results on type 1 diabetes at ADA 2011

The American research consortium Type 1 Diabetes TrialNet presented their results of a Phase II study with the antigen-based diabetes therapy Diamyd yesterday, June 27, at the American Diabetes Association 71st Scientific Sessions (ADA) in San Diego, California, USA, after the closing of the stock market.

28 Jun 2011

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it recently initiated a Phase 1 clinical trial of EVP-0962, its potent and selective gamma secretase modulator (GSM), in healthy volunteers.

27 Jun 2011

Positive results from Stealth's Bendavia Phase I renal impairment study

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia.

27 Jun 2011

Mortality, morbidity rates linked with AF remain 'unacceptably high' despite new treatments

Despite recent advances in the treatment of heart rhythm disturbances, mortality and morbidity rates associated with atrial fibrillation (AF) remain "unacceptably high", according to a new report.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

New automated sample preparation system developed for proteomic biomarker discovery and validation

A new automated sample preparation system based on Tecan's Freedom EVO- 200 liquid handling platform has been developed for proteomic biomarker discovery and validation in collaboration with the Translational Genomics Research Institute (TGen) and the Biodesign Institute at Arizona State University.

24 Jun 2011

Diamyd Medical to terminate US DiaPrevent Phase III study for type 1 diabetes

Diamyd Medical AB reports that the Company has decided to suspend dosing in a US Phase III study with the antigen-based therapy Diamyd and to initiate closure of the study.

23 Jun 2011

Key trigger to rare but deadly neurodegenerative disease

Jeremy Smith, Governor's Chair for Molecular Biophysics at the University of Tennessee, Knoxville, has helped reveal a key trigger of Gerstmann-Str-ussler-Scheinker (GSS) syndrome, a rare but deadly neurodegenerative disease. The finding could have far-reaching implications for the treatment of other neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's.

23 Jun 2011

Palatin receives U.S. patent titled ‘Amino Acid Surrogates for Peptidic Constructs'

Palatin Technologies, Inc. announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,964,181, titled "Amino Acid Surrogates for Peptidic Constructs."

22 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

Pulmatrix introduces novel iSPERSE inhaled dry powder drug delivery platform

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced the launch of iSPERSE, the company's novel inhaled dry powder drug delivery platform.

20 Jun 2011

Novel biomarker-development pipeline approach for human diseases

Researchers at Fred Hutchinson Cancer Research Center have demonstrated in mice that the performance of a novel biomarker-development pipeline using targeted mass spectrometry is robust enough to support the use of an analogous approach in humans.

20 Jun 2011

Innovative adult stem cell approach could help eliminate obesity

Innovative adult stem cell research by scientists at The University of Texas Health Science Center at Houston could aid efforts to apply the brakes to stem cells that produce the type of fat ringing the waists of millions. Research appeared today online ahead of the print issue of Cell Stem Cell.

17 Jun 2011

Key to remove stem cells responsible for fat expansion

Researchers may have found the key to developing a method to rid the body of stem cells responsible for driving fat expansion. According to a report in the June 16 Cell Stem Cell, a Cell Press publication, they've landed the first protein marker on the surface of those so-called adipose stromal cells (ASCs), which serve as progenitors of the cells that make up fat tissue.

17 Jun 2011

Adaptimmune melanoma trial opening

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.

16 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

Scientists discover new cell type in the immune system

A team of Australian scientists has discovered a new type of cell in the immune system. The new cell type, a kind of white blood cell, belongs to a family of T-cells that play a critical role in protection against infectious disease.

16 Jun 2011

ProImmune introduces new uniquely powerful protein and peptide array platform

ProImmune Ltd., a leader in services for understanding immune responses, announced today that it has launched ProArray Ultra, a uniquely powerful protein and peptide array platform, which is more sensitive than optimized ECL ELISA.

16 Jun 2011